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HIV testing in people with presumptive tuberculosis: 
time for implementation
Despite progress in the global response to the dual 
epidemic of HIV/AIDS and tuberculosis, an estimated 
1·8 million people died from AIDS-related diseases in 
2010,
1 including 350  000 deaths from HIV-associated 
tuberculosis.
2 In view of the fact that HIV/AIDS is 
treatable, albeit with lifelong therapy, and drug-sensitive 
tuberculosis is curable, such high mortality rates are 
unacceptable. WHO and the Joint UN Programme on 
HIV/AIDS (UNAIDS) have both embraced a bold vision 
of “zero new HIV infections, zero discrimination and 
zero AIDS-related deaths” by 2015, which has been 
reinforced by the 2012 World Tuberculosis Day theme 
that emphasises “zero tuberculosis deaths”. In March, 
2012, WHO launched its updated policy on collaborative 
tuberculosis and HIV activities,
3 with some important 
new recommendations, one of which was that routine 
HIV testing and counselling should be oﬀ  ered not only 
to patients diagnosed with tuberculosis, but also to 
all those being investigated for possible tuberculosis 
(hereafter referred to as presumptive tuberculosis). 
This recommendation implies that the HIV testing 
intervention should be moved upstream in the 
tuberculosis diagnostic pathway. In this Comment, we 
emphasise the logic behind this recommendation, argue 
that it will help to reduce mortality from HIV/AIDS and 
HIV-associated tuberculosis, and suggest how it can be 
implemented and monitored.
The results of several studies in sub-Saharan Africa
4,5 
and India
6,7 have shown that the prevalence of HIV in 
individuals with presumptive tuberculosis is as high 
as that in patients with diagnosed tuberculosis, with 
prevalence varying according to the epidemiological 
context. Some data show that people with 
presumptive tuberculosis who are sputum smear 
negative and infected with HIV generally fare poorly. 
For example, 63% of patients with presumptive 
tuberculosis in Zimbabwe were infected with HIV; 
85% had CD4 cell counts lower than 350 cells 
per μL; and during a 12-month follow up, 25% were 
diagnosed and treated for tuberculosis, 16% died, 
and only 15% started antiretroviral therapy.
4 These 
poor outcomes could be substantially improved by 
some simple interventions. First, if patients with HIV 
infection and presumptive tuberculosis are provided 
with structured HIV care that involves CD4 cell count 
assessment, co-trimoxazole preventive therapy, 
and antiretroviral therapy, this package will protect 
against serious HIV-related opportunistic infections, 
reverse immune deﬁ  ciency, and prevent tuberculosis.
8 
Second, such patients can be prioritised for new, 
high-sensitivity rapid diagnostics for tuberculosis, 
such as the nucleic acid ampliﬁ  cation test, Xpert MTB/
RIF (Cepheid, Sunnyvale, CA, USA). This test conﬁ  rms 
tuberculosis disease within 2 h, and provides additional 
information about rifampicin resistance, which helps 
to improve the treatment and management strategy. 
Third, if a diagnosis of active tuberculosis can be 
conﬁ  dently excluded, isoniazid preventive therapy can 
be used, for which there is increasing evidence for an 
additive and synergistic beneﬁ  t when combined with 
antiretroviral therapy.
9 
Although to move HIV testing upstream in settings 
of high HIV prevalence makes intuitive sense, further 
evidence is needed for whether such a policy actually 
reduces morbidity and mortality in settings of low HIV 
prevalence, in view of the resource implications. 
Although HIV testing and counselling in patients 
with diagnosed tuberculosis is widely implemented, 
monitored, and reported,
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with presumptive tuberculosis is not yet routine, and 
operational guidance is urgently needed. This is an area 
that demands high-quality, country-speciﬁ  c operational 
research, and diﬀ   erent models can be applied and 
tested in various settings.
10 For example, patients 
could be tested for HIV when they are identiﬁ  ed with 
presumptive tuberculosis or when they arrive at the 
laboratory to submit sputum samples. Follow-up will be 
crucial, and will need far better documentation than is 
recorded at present, with use of contact addresses and 
mobile phone numbers. An important question relates 
to monitoring—how and where should it be done, who 
should do it, and how should the results be reported? 
One possibility is to resurrect, renovate, or make better 
use of the so-called tuberculosis suspect register (after 
renaming it suitably), which is used in some countries 
and is controlled by the district or health facility 
tuberculosis oﬃ   cer.
10 An alternative model, which 
is being tested in India, is to record HIV testing and 
antiretroviral therapy uptake on the laboratory form 
and sputum laboratory register. The reporting of data 
should be based on quarterly cohorts, with cumulative 
data from peripheral to district to state to national 
levels that should ultimately be included in the annual 
WHO global tuberculosis and HIV reports.
In conclusion, we strongly believe that the shift of HIV 
testing upstream to include people with presumptive 
tuberculosis is feasible and could reduce HIV/AIDS 
and tuberculosis-related morbidity and mortality. 
Many unresolved questions remain about whether 
this approach applies equally to both generalised 
and concentrated HIV epidemics, and about how HIV 
testing should be done, monitored, and reported. 
No time can be wasted, and we need to move into an 
implementation phase and start ﬁ  nding the answers 
to these questions through an approach of learning by 
doing. 
*Ajay M V Kumar, Devesh Gupta, Radhe S Gupta, 
Srinath Satyanarayana, Nevin Wilson, Rony Zachariah, 
Stephen D Lawn, Anthony D Harries
International Union Against Tuberculosis and Lung Disease 
(The Union), South East Asia Oﬃ   ce, C-6, Qutub Institutional Area, 
New Delhi, 110016, India (AMVK, SS, NW); Central TB Division, 
Directorate General of Health Services (DG) and National AIDS 
Control Organization (RSG), Ministry of Health and Family 
Welfare, Government of India, New Delhi, India; Medical 
Department, Médecins Sans Frontières, Brussels Operational 
Centre, MSF-Luxembourg, Luxembourg (RZ); The Desmond Tutu 
HIV Centre, Institute for Infectious Disease and Molecular 
Medicine, Faculty of Health Sciences, University of Cape Town, 
Cape Town, South Africa (SDL); Department of Clinical Research, 
Faculty of Infectious and Tropical Diseases, London School of 
Hygiene and Tropical Medicine, London, UK (SDL, ADH); and 
International Union Against Tuberculosis and Lung Disease 
(The Union), Paris, France (ADH)
akumar@theunion.org
We declare that we have no conﬂ  icts of interest.
1  WHO, UNAIDS, Unicef. Global HIV/AIDS response. Epidemic update and 
health sector progress towards universal access. Progress Report 2011. 
Geneva: World Health Organization, 2011. 
2  WHO. Global tuberculosis control 2011. World Health Organization document 
WHO/HTM/TB/2011.16:1-246. Geneva: World Health Organization, 2011.
3  WHO. WHO policy on collaborative TB/HIV activities. Guidelines for 
national programmes and other stakeholders. World Health Organization 
document WHO/HTM/TB/2012.1:1-34. Geneva: World Health 
Organization, 2012.
4  Macpherson P, Dimairo M, Bandason T, et al. Risk factors for mortality in 
smear-negative tuberculosis suspects: a cohort study in Harare, Zimbabwe. 
Int J Tuberc Lung Dis 2011; 15: 1390–96.
5  Srikantiah P, Lin R, Walusimbi M, et al. Elevated HIV seroprevalence and risk 
behaviours among Ugandan TB suspects: implications for HIV testing and 
prevention. Int J Tuberc Lung Dis 2007; 11: 168–74.
6  Achanta S, Kumar AM, Nagaraja SB, et al. Feasibility and eﬀ  ectiveness of 
provider initiated HIV testing and counseling of TB suspects in 
Vizianagaram district, south India. PLoS One 2012; 7: e41378.
7  Naik B, Kumar AMV, Lal K, et al. HIV prevalence among persons suspected 
of tuberculosis: policy implications for India. J Acquir Immune Deﬁ  c Syndr 
2012; 59: e72–76.
8  Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention 
of tuberculosis in adults with HIV: a systematic review and meta-analysis. 
PLoS Med 2012; 9: e1001270.
9  Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and 
tuberculosis— science and implementation to turn the tide and reduce 
deaths. J Int AIDS Soc 2012; 15: 17396.
10  Harries AD. Paying attention to tuberculosis suspects whose sputum 
smears are negative. Int J Tuberc Lung Dis 2011; 15: 427–28.